Vir Biotechnology Inc. (NASDAQ: VIR) reported Q2 EPS of $0.47, $0.14 better than the analyst estimate of $0.33. Revenue for the quarter came in at $238.94 million versus the consensus estimate of $135.88 million.

For earnings history and earnings-related data on Vir Biotechnology Inc. (VIR) click here.